BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2021 RESULTS WEBCAST
Bergen, Norway, 8 February 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the fourth quarter 2021 on Wednesday 16 February 2022. A briefing by BerGenBio’s senior management team will take place at 10:00 am CET via a webcast presentation, followed by a Q&A session. The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section. A recording will be available shortly after the webcast has finished.